COVID-19
Conditions
Interventions
Intervention Group:Conventional therapy+Lianhua Qingke Tablets, 4 tablets/time, 3 times a day
Control group:Conventional therapy
Sponsors
Xingtai People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with novel coronavirus pneumonia diagnosed by etiology test; 2. Age above 18 (inclusive), male or female; 3. Any of the main symptoms (fever, cough, expectoration, sore throat, dry throat) at the time of admission; 4. Sign the written informed consent voluntarily before the start of the study.
Exclusion criteria
Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, gastroesophageal reflux disease, and pulmonary dysplasia 2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory system bacterial infection such as suppurative tonsillitis, acute tracheobronchitis, sinusitis, otitis media and other respiratory diseases that affect clinical trial evaluation. Chest CT confirmed the presence of severe pulmonary interstitial disease, bronchiectasis and other basic lung diseases 3. Severe pneumonia requiring mechanical ventilation 4. According to the judgment of the investigator, the patient may suffer from diseases that may affect the patient's participation in the trial or the outcome of the study, including malignant diseases, autoimmune diseases, liver and kidney diseases, blood diseases, nervous system diseases, and endocrine diseases; Now he has diseases that seriously affect the immune system, such as human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc 5. Pregnant women or lactating women; 6. Patients who have participated in other clinical trials in the past three months; 7. Allergic constitution, such as those who have a history of allergy to two or more drugs or food, or who are known to be allergic to the ingredients of this drug; 8. The investigator believes that there are any factors that are not suitable for inclusion or affect the efficacy evaluation of the subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The disappearance rate and median time of clinical symptoms; | — |
Secondary
| Measure | Time frame |
|---|---|
| Single symptom disappearance rate and main symptom disappearance time;Proportion of converting to ordinary type;Proportion of aggravation during treatment;Time and rate of first nucleic acid turning negative; | — |
Countries
China
Contacts
Public ContactZhiguo Gao
Xingtai People's Hospital
Outcome results
None listed